Control
Jul 28 |
Lopinavir/ritonavir for COVID-19: real-time meta analysis of 17 studies | |
| Meta analysis using the most serious outcome reported shows 10% [-5‑28%] higher risk, without reaching statistical significance. Control Lopinavir/ritonavirLopinavir/r.. All data and sources to reproduce this analysis are in th.. | ||
Aug 13 2024 |
et al., Cureus, doi:10.7759/cureus.66798 | Anticoagulant Use in COVID-19 Patients: A Longitudinal Study From Zanjan, Iran |
| 163% higher mortality (p<0.0001). Retrospective 831 hospitalized COVID-19 patients showing higher mortality with lopinavir/ritonavir treatment in unadjusted results. | ||
Jul 30 2024 |
et al., Journal of Controversies in Obstetrics & Gynecology and Pediatrics, doi:10.51271/JCOGP-0035 | Is vitamin D level important in pregnant women with COVID-19? |
| 136% higher hospitalization (p=0.43). Retrospective 125 pregnant women hospitalized with COVID-19 in Turkey, showing no significant difference in hospitalization length with HCQ, and longer hospitalization with lopinavir/ritonavir use. | ||
Mar 31 2023 |
et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2022.12.028 | Lopinavir/ritonavir for treatment of non-hospitalized patients with COVID-19: a randomized clinical trial |
| 203% higher mortality (p=0.49), 20% higher hospitalization (p=0.78), and 3% worse recovery (p=0.88). RCT 437 non-hospitalized COVID-19 patients showing no significant differences with lopinavir/ritonavir (LPV/r) treatment. | ||
Apr 16 2022 |
et al., Pediatric Drugs, doi:10.1007/s40272-022-00500-7 | Slower Recovery with Early Lopinavir/Ritonavir use in Pediatric COVID-19 Patients: A Retrospective Observational Study |
| 96% lower hospital discharge (p<0.0001) and 96% worse recovery (p<0.0001). Retrospective 933 pediatric COVID-19 patients in Hong Kong showing worse outcomes with early lopinavir/ritonavir (LPV/r) use. | ||
Feb 15 2022 |
et al., PLOS Medicine, doi:10.1371/journal.pmed.1004120 (date from preprint) | Favipiravir, lopinavir-ritonavir, or combination therapy (FLARE): A randomised, double-blind, 2 × 2 factorial placebo-controlled trial of early antiviral therapy in COVID-19 |
| 200% higher hospitalization (p=1) and 7% improved viral clearance (p=0.56). 240 patient RCT comparing favipiravir, favipiravir + LPV/r, LPV/r, and placebo, showing improved viral clearance with favipiravir, but no significant difference for LPV/r. Efficacy was lower in the combined favipiravir + LPV/r arm, where .. | ||
Dec 31 2021 |
et al., eClinicalMedicine, doi:10.1016/j.eclinm.2021.101188 | Post-exposure Lopinavir-Ritonavir Prophylaxis versus Surveillance for Individuals Exposed to SARS-CoV-2: The COPEP Pragmatic Open-Label, Cluster Randomized Trial |
| 630% higher progression (p=0.02) and 40% fewer symptomatic cases (p=0.17). Open-label, cluster-randomized RCT 318 asymptomatic close contacts in Switzerland and Brazil showing no statistically significant difference in symptomatic COVID-19 at 21 days with LPV/r prophylaxis. The mid-trial changes in allocation an.. | ||
Jul 12 2021 |
et al., Intensive Care Medicine | Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial |
| 54% higher mortality (p=0.02). Very late stage RCT with 50 ICU patients treated with HCQ, 255 lopinavir-ritonavir patients, and 27 combined therapy patients, showing higher mortality with all treatments. Authors do not report results for patients in the moderate state,.. | ||
Jun 9 2021 |
et al., Frontiers in Medicine, doi:10.3389/fmed.2021.639970 | Lopinavir/Ritonavir and Darunavir/Cobicistat in Hospitalized COVID-19 Patients: Findings From the Multicenter Italian CORIST Study |
| 6% lower mortality (p=0.52). Retrospective 3,451 hospitalized COVID-19 patients in Italy showing higher mortality with darunavir/cobicistat. | ||
Apr 28 2021 |
et al., Respiratory Medicine, doi:10.1016/j.rmed.2021.106433 | The predictors of COVID-19 mortality in a nationwide cohort of Turkish patients |
| 118% higher mortality (p=0.38). Retrospective 1,500 hospitalized late stage (median SaO2 87.7) patients in Turkey, showing no significant difference in mortality with treatment. | ||
Apr 22 2021 |
et al., JAMA Network Open, doi:10.1001/jamanetworkopen.2021.6468 | Effect of Early Treatment With Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients With COVID-19 The TOGETHER Randomized Clinical Trial |
| 86% higher mortality (p=1) and 16% higher hospitalization (p=0.72). Early terminated RCT in Brazil showing no significant differences with lopinavir/ritonavir treatment. | ||
Dec 31 2020 |
et al., Med, doi:10.1016/j.medj.2020.04.001 | Efficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients with Mild/Moderate COVID-19: An Exploratory Randomized Controlled Trial |
| 100% higher progression (p=0.46) and 3% faster viral clearance (p=0.84). RCT 86 mild/moderate COVID-19 patients showing no significant difference in outcomes with lopinavir/ritonavir or arbidol compared to control. | ||
Oct 31 2020 |
et al., The Lancet, doi:10.1016/S0140-6736(20)32013-4 | Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial |
| 3% higher mortality (p=0.6), 15% higher ventilation (p=0.15), and 2% lower hospital discharge (p=0.53). RCT with 1,616 hospitalized COVID-19 patients showing no significant differences with lopinavir-ritonavir treatment compared to usual care. | ||
Oct 20 2020 |
et al., Biomedical Reports, doi:10.3892/br.2020.1375 | Retrospective analysis of the effect of current clinical medications and clinicopathological factors on viral shedding in COVID‑19 patients |
| 45% improved viral clearance (p=0.01). Retrospective 186 hospitalized COVID-19 patients showing faster viral clearance with lopinavir/ritonavir. There may be significant confounding by indication - authors classify cases as non‑severe vs severe, but severity is not included in.. | ||
Oct 15 2020 |
, NEJM, doi:10.1056/NEJMoa2023184 (date from preprint) | Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results |
| no change in mortality (p=1) and 2% higher ventilation (p=0.89). WHO SOLIDARITY open-label RCT showing no significant difference in outcomes with lopinavir/ritonavir treatment. | ||
Oct 6 2020 |
et al., medRxiv, doi:10.1101/2022.02.16.22271064 | An open-label randomized, controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-beta-1a and hydroxychloroquine in hospitalized patients with COVID-19 - Final results from the DisCoVeRy trial |
| 36% higher mortality (p=0.39) and 26% improved viral clearance (p=0.65). Early terminated very late stage (95% on oxygen at baseline) DISCOVERY trial showing no significant differences with lopinavir/ritonavir. | ||
Aug 1 2020 |
et al., Zhonghua Nei Ke Za Zhi, doi:10.3760/cma.j.cn112138-20200227-00147 | The efficacy and safety of lopinavir/ritonavir and arbidol in patients with coronavirus disease 2019 |
| 21% slower viral clearance (p=0.008). Retrospective 178 hospitalized COVID-19 patients in China | ||
Jul 14 2020 |
et al., Frontiers in Pharmacology, doi:10.3389/fphar.2020.01071 | No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, Open-Labeled Prospective Study |
| 6% longer hospitalization (p=0.68), 33% faster recovery (p=0.32), 18% faster improvement (p=0.07), and 15% slower viral clearance (p=0.41). RCT 101 mild to moderate COVID-19 patients showing no significant difference in antiviral effectiveness among three treatment regimens: ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha, and ribavirin plus lopinav.. | ||
May 19 2020 |
et al., European Respiratory Journal, doi:10.1183/13993003.00799-2020 | Factors associated with prolonged viral shedding and impact of lopinavir/ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection |
| 40% improved viral clearance (p=0.01). Retrospective 120 hospitalized non-critically ill COVID-19 patients showing that early administration of lopinavir/ritonavir was associated with shorter duration of SARS-CoV-2 RNA shedding. | ||
May 7 2020 |
et al., New England Journal of Medicine, doi:10.1056/NEJMoa2001282 | A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 |
| 23% lower mortality (p=0.39), 29% greater improvement (p=0.19), and 4% improved viral clearance (p=1). RCT 199 hospitalized COVID-19 patients showing no significant difference with lopinavir-ritonavir treatment. 28-day mortality was lower in the treatment group, without statistical significance. 3 treatment patients died within 24 hours af.. | ||
Mar 31 2020 |
et al., The Lancet, doi:10.1016/S0140-6736(20)30566-3 | Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study |
| 10% slower viral clearance (p=0.06). Retrospective 191 hospitalized COVID-19 patients in China showing no significant difference in viral clearance with lopinavir/ritonavir. | ||
Please send us corrections, updates, or comments.
c19early involves the extraction of 200,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. IMA and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.